.Learn about Overdrive technology
The lntellis™ with AdaptiveStim™ rechargeable neurostimulator is powered by proprietary Overdrive™ battery technology. It is designed to overcome limitations with other SCS systems and is optimized for the increased energy demands of High Dose (HD) therapy.
DTM™ SCS therapy is a proprietary therapy inspired by science and rooted in pre-clinical research, and adapted to provide superior clinical outcomes.
The DTM™ SCS 12-month RCT proved sustained superiority compared to conventional stimulation.
The Medtronic adaptor extension creates a connection with certain Boston Scientific™ or Nevro™ leads.† This enables patients with existing leads to gain access to superior DTM™ SCS therapy on Intellis™ INS.1 For patients wanting rapid recharge with Intellis™ INS or recharge-free convenience with Vanta™ INS, the adaptor extension allows you to offer meaningful pain relief with DTM™ SCS endurance therapy.3
Access prescriber, implant, MRI, and other manuals on the Medtronic Manual Library. Search by the product name (Intellis™) or model number (97715). You may also call 800-961-9055 for a copy of a manual.
Under specific conditions. Refer to product labeling for full list of conditions. Patients with non-Medtronic leads and an EMBSNV20 adaptor extension are not eligible for an MRI.
Third party brands are trademarks of their respective owners. All other brands are trademarks of a Medtronic company.
Fishman M, Cordner H, Justiz R, et al. 12-Month Results from multicenter, open-label, randomized controlled clinical trial comparing differential target multiplexed spinal cord stimulation and traditional spinal cord stimulation in subjects with chronic intractable back pain and leg pain. Pain Pract. 2021; 00: 1–12. doi: 10.1111/papr.13066.
Desai MJ, Hargens LM, Breitenfeldt MD, et al. The rate of magnetic resonance imaging in patients with spinal cord stimulation. Spine. 2015;40(9):E531–537.
Peacock, Provenzano, Fishman, et al. A prospective multi-center study of a differential target multiplexed™ stimulation derivative in therapy-naive patients: Primary endpoint and 3-month outcomes. Poster presented at: North American Neuromodulation Society (NANS) annual meeting. Jan. 13–15, 2022.
The Bluetooth® word mark and logos are registered trademarks owned by Bluetooth SIG, Inc. and any use of such marks by Medtronic is under license.™